Siemens Healthineers Deploys AI-Based Diagnostic Analyzer at Mahajan Imaging & Labs

This AI-enhanced analyzer aims to streamline patient care by offering faster and more precise results.

Siemens Healthineers has introduced its Atellica CI diagnostic analyzer at Mahajan Imaging & Labs, marking a significant advancement in diagnostic testing. 

This AI-enhanced analyzer aims to streamline patient care by offering faster and more precise results.

Dr Harsh Mahajan, founder of Mahajan Imaging & Labs, said, "The deployment of the Atellica CI analyzer marks a new phase in our commitment to providing fast and accurate diagnostic results. This technology will significantly enhance our ability to deliver timely patient care, especially in critical situations."

The Atellica CI analyzer takes processing over 200 parameters across 20 disease states within a compact design. Its microvolume technology allows efficient testing from small sample volumes. 

This feature is crucial for pediatric and critical care cases where minimal sample sizes are required.

The analyzer can complete critical tests in just 14 minutes, a notable improvement over the 22 to 40 minutes required by traditional methods. 

Emergency assays are processed even more quickly, with results available 10 minutes after a one-minute sample aspiration. The analyzer also includes a new 'Enhanced Liver Fibrosis (ELF)' test, designed to improve the prognosis of liver fibrosis, a significant health issue in India.

About the AI-Based Analyzer

The Atellica CI analyser, approved by the US Food and Drug Administration (FDA), is aligned with sustainability standards. Compared to other diagnostic tools, it reduces water and tube usage and generates less plastic waste. 

The system further incorporates AI technology to minimize manual errors and enhance test accuracy. This is particularly relevant for tests that can be affected by factors such as biotin or gummy intake.

The analyzer supports a variety of diagnostic parameters, including FMF-approved dual markers for maternal screening, AMH for ovarian reserve assessment, and tests for active vitamin B12 and ferritin, crucial for women’s health. 

It also provides oncology markers such as PSA for prostate cancer and markers for ovarian cancer, as well as tests for active vitamin D levels.

"Our goal with the Atellica CI is to advance diagnostic capabilities while adhering to sustainability standards. Integrating AI technology aims to improve both the speed and precision of test results, making a substantial impact on patient care," a spokesperson from Siemens Healthineers’ shared.